Prospective Evaluation of erectile function after Collagenase Therapy in Patietens with Peyronies Disease

Prospective Evaluation of erectile function after Collagenase Therapy in Patietens with Peyronies Disease - ERECT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010450

Enrollment

Registered

2016-05-03

Start date

2015-10-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N48.6

Interventions

Group 1: Following therapy is intended: - 1 injection every 4 weeks, totaling 3 injections - between injections patients are advised to perform penile modeling on a daily basis (10min) - Injection d

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with penile Peyronie´s Disease stable disease for 6 Months palpable penile Plaque penile deviation (>30°) collagenase therapy with Xiapex

Exclusion criteria

Exclusion criteria: Patients <18ys, missing consent to study, penile deviation of other causes, contraindications as listed by package insert

Design outcomes

Primary

Measure	Time frame
Improvement of erectile function (IIEF and Peyronie questionaire), decreased curvature (>30°) Follow up 3, 6, 9, 12, 18, 24 months after therapy (IIEF and Peyronie questionaire)	—

Secondary

Measure	Time frame
Quality of life Sexual and erectile function (IIEF, PDQ questionaires) Follow up 3,6,9,12,18,24 months after therapy	—

Countries

Germany

Contacts

Public ContactDaniel Schlager

Universitätsklinikum Freiburg Abteilung für Urologie

daniel.schlager@uniklinik-freiburg.de0761 270 28910

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026